Immunotherapy Agent Shows Potential to Inhibit Tumor Growth in Lymphoma Models
News
Surface Oncology recently announced promising outcomes of its immunotherapy agent SRF231, a human CD47 antibody, in clearance of tumor cells both alone and when combined with other cancer drugs. SRF231 also demonstrated ... Read more